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Abstract: This present paper deals with the development and validation of a stability indicating high performance liquid chromatographic 
method for the quantitative determination of Memantine hydrochloride. Memantine hydrochloride was derivatized with 0.015 M 
9-fluorenylmethyl chloroformate (FMOC) and 0.5 M borate buffer solution by keeping it at room temperature for about 20 minutes and 
the chromatographic separation achieved by injecting 10 µL of the derivatized mixture into a Waters HPLC system with photodiode 
array detector using a kromasil C18 column (150 × 4.6 mm), 5 µ. The mobile phase consisting of 80% acetonitrile and 20% phosphate 
buffer solution and a flow rate of 2 milliliter/minute. The Memantine was eluted at approximately 7.5 minutes. The volume of FMOC 
used in derivatization, concentration of FMOC and derivatization time was optimized and used. Forced degradation studies were per-
formed on bulk sample of Memantine hydrochloride using acid (5.0 Normal (N) hydrochloric acid), base (1.0 N sodium hydroxide), oxi-
dation (30% hydrogen peroxide), thermal (105°C), photolytic and humidity conditions. The developed LC method was validated with 
respect to specificity, precision (% RSD about 0.70%), linearity (linearity of range about 70–130 µg/mL), ruggedness (Overall % RSD 
about 0.35%), stability in analytical solution (Cumulative % RSD about 0.11% after 1450 min.) and robustness.
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Introduction
Memantine hydrochloride (1-amino3, 5-dimethylad-
amantane hydrochloride) (Fig. 1) is a tricyclic amine 
chemically and pharmacologically related to the anti-
viral prototype amantadine and its α-methyl deriva-
tive rimantadine. Amantadine and rimantadine have 
been approved in the U.S. for the prophylaxis and 
treatment of influenza. Amantadine is also approved 
for the treatment of Parkinsonism. Memantine is used 
in  Parkinson’s  disease  and  movement  disorders.1 
Recently, it has been demonstrated to be useful in 
dementia syndrome.2 Memantine is a noncompetitive 
NMDA antagonist in clinical use for many years in 
Europe. It produces few side effects, even among the 
geriatric patients, who are typical candidates for this 
drug.3,4
The NMDA receptor, a glutamate receptor sub-
type,  may  play  a  significant  role  in  the  develop-
ment  and  maintenance  of  dependence  on  opoids, 
nicotine, and cocaine.5,6 In laboratory animals, low 
doses of NMDA antagonists inhibit the development 
of opioid tolerance and dependence,7 and attenuate 
established morphine (mµ) opioid tolerance.8 It has 
been suggested that the development of tolerance, 
dependence  and/or  sensitization  to  virtually  all 
psychoactive drugs can be attenuated or abolished 
by pretreatment with NMDA antagonist.9 As such, 
Memantine is a promising agent for the treatment 
of substance use disorders. Unlike other noncom-
petitive NMDA antagonists, such as phencyclidine 
and ketamine, memantine has rarely been associated 
with the significant adverse side effects of agitation, 
confusion, and psychosis.10,11
Memantine free base, which is both highly basic 
(pKa  10.42)  and  lipophilic  (log  P  3.28),  suggests 
that  it  may  show  binding  to  various  derivatiza-
tion agent like FMOC, dansyl chloride etc., due to 
ionic interaction of its basic primary amine group. 
Since Memantine lacks useful chromophores, it can-
not  be  readily  assayed  by  HPLC-UV  techniques.12 
Consequently, Memantine has to be derivatized for 
HPLC-fluoresence measurement,13–15 determined by 
capillary zone electrophoresis with indirect UV detec-
tion,16  measured  by  GC  without  derivatization,17–20 
or for enhanced sensitivity derivatized and analyzed 
by  GC.21–24  Dansyl  chloride  and  9-fluorenylmethyl 
chloroformate react readily with most primary and 
secondary amines in alkaline buffer, and it is regarded 
as the derivatizing reagent of choice in the prepara-
tion of highly fluorescent compounds.25,26
The purpose of this study was to develop, opti-
mize and validate derivatized method with direct 
UV-detection  for  the  quantitative  determination 
of Memantine hydrochloride drug substance. This 
method also has advantages over some literature 
technique  as  mentioned  above  references,13–20 
like  here  Mementine  hydrochloride  response  is 
measured  by  direct  UV  detection  with  enhanced 
sensitivity  and  method  is  simpler,  highly  repro-
ducible,  specific  and  accurate,  compare  to  using 
complex techniques like use of fluorescence detec-
tor, or by using capillary zone electrophoresis tech-
nique or GC technique.
experimental
reagents and chemicals
Hexylamine  (99%)  was  purchased  from  Aldrich 
(USA),  9-fluorenylmethyl  chloroformate  (98% 
GR  grade)  was  purchased  from  Fluka, Acetonitrile 
(HPLC  grade),  Potassium  dihydrogen  orthophos-
phate (AR grade), Boric acid (AR grade), Potassium 
chloride (AR grade), Sodium hydroxide (AR grade), 
Orthophosphoric acid (88% AR grade) were purchased 
from Qualigens (India) and Memantine hydrochloride 
was obtained from Ranbaxy Labs. Ltd. (India). All the 
above materials were used without any further purifi-
cation. Water (HPLC grade) was used for the prepara-
tion of solutions.
NH2
CH3 CH3
HCl
Figure 1. structure of memantine hydrochloride. Molecular formula: C12 
h21n-hCI: molecular mass: 215.76 (free base: 179.20): partition coef-
ficient, log(P): 3.28: basicity. pKa: 10.42: solubility of the hydrochloride 
salt: 3.5% in a ph 6.5 aqueous solution at 25 °C.Determination of Memantine hydrochloride with UV-detection using precolumn derivatization
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Chromatography
The  analytical  separations  were  carried  out  on 
a  Waters  HPLC  system,  equipped  with  a  2695 
separation  module  and  2996  photodiode  array 
detector.  The  analytical  column  was  a  kroma-
sil C18 (150 × 4.6 mm) 5 µ, (Flexit). The mobile 
phase consisted of premixed and degassed solution 
of  buffer  and  acetonitrile  in  the  ratio  of  [20:80] 
[v/v].  The  mobile  phase  was  filtered  through  a 
0.45 µm membrane filter. The diluent contains pre-
mixed and degassed solution of 0.05 Molar (M) 
borate buffer pH 8.5 and acetonitrile in the ratio 
of [50:50] (v/v). The flow rate was 2 mL/min and 
runtime was 12 minute. Column temperature was 
maintained at 30°C. UV detection was measured 
at 265 nm and the volume of sample injected was 
10 µL. The control of the HPLC system and data 
collection was by Empower software.
Derivatization process of standard  
and sample solution
Standard and all sample stock solutions at 1 gram 
per liter (g/L) were prepared by dissolving Meman-
tine  hydrochloride  in  diluent. The  derivatization 
process was carried out by transferring 5 mL of stan-
dard/sample stock solution into 50 mL volumetric 
flask. Add 4 mL each of 0.015 M FMOC solution 
and 0.5 M borate buffer solution. Shake well and 
keep it at room temperature for 20 minutes. Make 
up the volume with diluent and inject. The final 
concentration is 0.1 g/L.
Method optimization parameters
Some chromatographic parameters such as derivatization 
process time optimization, FMOC volume optimization, 
FMOC concentration optimization were investigated to 
obtain a good, specific and accurate method.
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Minutes
Sample Name MP-1; Vial 2; Injection 1; Date Acquired 28/03/2007 3:04:36 PM; Date Processed
28/03/2007 6:54:36 PM; Run Time 12.00; Injection Volume 10.00; Total Area 2530788; Processed
Channel Descr. PDA 265.0 nm
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Figure 2. Chromatogram and Peak purity plot of Memantine in sample.
Abbreviations: PA, Purity angle; Th, Purity threshold.narola et al
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Derivatization process time optimization  
for standard and sample solution
Memantine  hydrochloride  sample  solution  was 
treated as procedure given above (under derivatiza-
tion process of standard and sample solution) by keep-
ing solution at room temperature for 0,5,10,15,20,30 
and 60 minutes to optimize it. The optimized reac-
tion time was found by plotting the peak area counts 
of Memantine versus the reaction time. After 5 min-
utes the peak area counts observed to be linear with 
respect to time.
FMOC volume optimization for standard  
and sample solution
Solution  was  treated  as  procedure  given  above 
(under derivatization process of standard and sample 
solution)  by  adding  different  volume  of  FMOC 
solution i.e. 1 mL, 2 mL, 3 mL, 4 mL, 5 mL and 
10 mL to ensure complete reaction of Memantine 
hydrochloride. The optimized volume was found by 
plotting the peak area counts of Memantine versus 
the volume of FMOC added in mL. After 2 mL the 
peak area counts observed to be linear with respect 
to added volume.
FMOC concentration optimization  
for standard and sample solution
Solution  was  treated  as  procedure  given  above 
(under derivatization process of standard and sam-
ple  solution)  by  adding  different  concentration 
of FMOC solution i.e. 0.01 M, 0.015 M, 0.02 M, 
0.04 M and 0.06 M to ensure complete reaction of 
Memantine HCL. The optimized concentration was 
found by plotting the peak area counts of Meman-
tine versus the FMOC concentration in M. Peak area 
counts observed to be linear with respect to each 
FMOC concentration.
Results and Discussion
Method optimization parameters
Based on method optimization parameter experiment, 
it can easily conclude that selected derivatization pro-
cess time (i.e. 20 minutes), FMOC volume (i.e. 4 mL) 
and concentration of FMOC (i.e. 0.015 M) were suf-
ficient for derivatization of Memantine hydrochloride 
drug substance.
Method validation
Specificity
 i.   Sample solution was analyzed as per the method 
and purity of Memantine peak was checked. The 
purity data of Memantine peak indicates that the 
peak is homogeneous (Fig. 2).
ii.   Sample solution spiked with the known related 
substances  of  Memantine  hydrochloride 
Table 1. Specificity.
sample  n  Mean assay  
(% w/w)
% difference 
Unspiked  
sample
3 100.2
0.1
spiked  
sample
3  100.3 
Table 2. Forced degradation studies.
Mode of  
degradation
condition  Assay  
(% w/w)
% degradation  
w.r.t. control
purity  
angle
purity  
threshold
Control no treatment 99.5 – – –
Acid degradation 5 n  
hydrochloric acid/10 mL
Initial 88.8 11 0.058 1.013
Alkali degradation 1 n  
sodium hydroxide/5 mL
room temperature 
(rT)/5 min.
77.0 23 0.062 1.047
Peroxide degradation  
30% w/v hydrogen  
peroxide/10 mL
80°C/15 minute 70.8 29 0.061 1.045
Thermal degradation 105°C/114 hrs.  
and 24 min.
100.5 – 0.070 1.014
Photolytic degradation 2600 Lux/114 hrs.  
and 17 min.
100.8 – 0.063 1.013
humidity degradation  25°C/92% rh/114 hrs.  
and 19 min.
99.4  –  0.061  1.012 Determination of Memantine hydrochloride with UV-detection using precolumn derivatization
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was  analyzed  in  triplicate  and  the  purity  of 
Memantine peak was checked. The purity data 
of  Memantine  peak  indicates  that  the  peak  is 
homogeneous and has no co eluting peaks indi-
cating  specificity  of  the  method  (Fig.  3). The 
specificity of the method is also indicated by % 
difference of 0.1% between the mean of assay 
values of unspiked and spiked samples as shown 
in Table 1. (Acceptance criteria: % Difference 
should not be more than 1).
Table 3. system precision.
Injection no. Area counts   
(µV*sec.)
1 2497768
2 2501106
3 2505389
4 2527928
5 2542869
6 2512614
Mean 2514612
standard deviation (sD) 17498
RsD (%) 0.70
Table 4. Method precision.
sample no.  Assay  
(% w/w)
1 100.5
2 100.2
3 100.0
4 100.4
5 100.0
6 99.8
Mean 100.2
sD 0.27
RsD (%) 0.27
A
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Minutes
Sample Name Specificity-1; Vial 9; Injection 1; Date Acquired 28/03/2007 5:51:55 PM; Date
Processed 28/03/2007 7:55:54 PM; Run Time 12.00; Injection Volume 10.00; Total Area 2518430;
Processed Channel Descr. PDA 265.0 nm
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Figure 3. Chromatogram and Peak purity plot of Memantine in sample spiked with known related substances of Memantine hydrochloride drug substance.narola et al
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Table 6. ruggedness.
sample no. Assay (% w/w)
set I set II
1 100.5 100.5
2 100.2 100.6
3 100.0 100.9
4 100.4 100.1
5 100.0 99.9
6 99.8 100.7
Mean 100.2 100.5
sD 0.27 0.38
RsD (%) 0.27 0.38
Overall mean 100.3
Overall sD 0.35
Overall RsD (%) 0.35
set I II
Analyst 1 2
Instrument no. A B
column no. X Y
All the above studies indicate that the method is 
specific.
Forced degradation study
A  forced  degradation  study  was  carried  out  on 
Memantine hydrochloride drug substance according 
to the following conditions
  i.    Hydrolytic and Oxidative degradation
    Sample was separately treated with 5 N hydro-
chloric acid, 1 N sodium hydroxide and 30% w/v 
hydrogen peroxide solutions. Solutions of these 
samples  were  prepared  as  per  the  conditions 
given in Table 2 and analyzed by the proposed 
method.
 ii.    Thermal degradation
    Sample was subjected to thermal degradation by 
keeping at 105°C for 114 h and 24 min., followed 
by analysis by the proposed method.
iii.    Photolytic degradation
    Photolytic  degradation  study  was  carried  out 
by exposing the sample to light in a photolytic 
chamber at 2600 Lux for 114 h and 17 min., fol-
lowed by analysis by the proposed method.
iv.  Humidity degradation
    Sample was subjected to humidity degradation 
by keeping at 25°C at 92% RH for 114 h and 
19 min., followed by analysis by the proposed 
method.
Using peak purity test, the purity of Memantine peak 
was checked at every stage of the above mentioned 
Table 7. stability in analytical solution.
Time (min.)  Area counts  
(µV*sec.)
cumulative   
RsD (%)
Initial 2445873 –
61 2445792 0.00
123 2446698 0.02
184 2442988 0.07
306 2444389 0.06
427 2445639 0.05
548 2446246 0.05
730 2444538 0.05
911 2444743 0.05
1093 2445827 0.04
1274 2442652 0.05
1356 2442425 0.06
1399 2441395 0.07
1450 2436921 0.11
Table 5. Linearity of response.
conc. (µg/ml)  Average area  
counts (µV*sec.)
70.70 1782336
80.80 1976560
90.91 2276081
101.01 2554214
111.11 2788688
121.21 3017940
131.31 3281125
slope 25073
Intercept –7225
cc 0.99911
Abbreviation: CC, Correlation coefficient.
study. The peak purity data show that the Memantine 
peak is homogeneous and has no co eluting peaks indi-
cating that the method is stability indicating and spe-
cific. Data is summarized in Table 2.Determination of Memantine hydrochloride with UV-detection using precolumn derivatization
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Precision
system precision
Six replicate injections of standard solution were given 
into the HPLC system. Data along with the % RSD 
of area counts for Memantine peak shown in Table 3 
indicate an acceptable level of precision for the ana-
lytical system. (Acceptance criteria: Relative standard 
deviation (RSD) should not be more than 1.0%).
Method precision
Six samples of a single batch of Memantine hydro-
chloride  drug  substance  were  analyzed  as  per  the 
proposed method. Data is shown in Table 4. The % 
RSD value indicates that the method has an accept-
able  level  of  precision.  (Acceptance  criteria:  RSD 
should not be more than 2%).
Linearity of response
The linearity of the method should be tested in order 
to demonstrate a proportional relationship of response 
versus analyte concentration over the working range. 
It is usual practice to perform linearity experiments 
over a wide range of analyte. This gives confidence 
that the response and concentration are proportional 
and  consequently  ensures  that  calculations  can  be 
performed using a single reference standard/working 
standard,  rather  than  the  equation  of  a  calibration 
line. The linearity of response for Memantine hydro-
chloride was determined in the range of 70.70 µg/mL 
to 131.31 µg/mL. Data shown in Table 5 and rep-
resented  graphically  in  Figure  4  indicate  that  the 
response is linear over the specified range. (Accep-
tance criteria: Correlation coefficient should not be 
less than 0.999).
ruggedness
Method ruggedness was verified by analyzing six 
samples of a single batch of Memantine hydrochlo-
ride drug substance by two different analysts using 
two different instruments and columns on different 
days.  The  mean  standard  deviation  and  %  RSD 
for the two sets of data is shown in Table 6. Rug-
gedness  of  the  method  is  shown  by  the  overall 
RSD value of 0.35% between the two sets of data. 
(Acceptance criteria: Overall RSD should not be 
more than 2%).
stability in analytical solution
A  sample  solution  of  Memantine  hydrochlo-
ride  drug  substance  was  prepared  and  kept  at 
room temperature. It was analyzed initially and at 
different time intervals. Data is shown in Table 7. As 
the cumulative % RSD up to 1450 min., meets the 
Figure 4. Linearity plot of memantine hydrochloride
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Table 8. robustness.
s.no. Assay (% w/w)
set I set II set III set IV set V set VI set VII set VIII
1 100.5 101.0 100.8 100.4 100.2 100.4 100.4 99.9
2 100.2 100.8 101.0 100.7 100.6 100.2 100.3 100.4
3 100.0 100.3 100.7 101.1 100.8 100.0 100.0 100.7
4 100.4 – – – – – – –
5 100.0 – – – – – – –
6 99.8 – – – – – – –
Mean 100.2 100.7 100.8 100.7 100.5 100.2 100.2 100.3
sD 0.27 0.36 0.15 0.35 0.31 0.20 0.21 0.40
RsD (%) 0.27 0.36 0.15 0.35 0.31 0.20 0.21 0.40
Overall mean 100.3 100.4 100.3 100.3 100.2 100.2 100.2
Overall sD 0.39 0.41 0.40 0.32 0.23 0.24 0.31
Overall RsD (%) 0.39 0.41 0.40 0.32 0.23 0.24 0.31
Set I, Control (Proposed method); Set II, Variation in flow rate (–10%); Set III, Variation in flow rate (+10%); set IV, Variation in organic content in mobile 
phase (–2%); set V, Variation in organic content in mobile phase (+2%); set VI, Variation in wavelength (λ = 260 nm); set VII, Variation in wavelength 
(λ = 270 nm); set VIII, Column oven temperature (35°C).
a simple and very effective means of enhancing the 
chromatographic detection of the compound.
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